

Monday 9 June 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Tuesday 3 June 2025. I am pleased to confirm the following.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)-11
- Abemaciclib + Fulvestrant-3
- Alpelisib + Fulvestrant-2
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide-10
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel-6
- Atezolizumab-1
- Capivasertib-0
- Capecitabine as a single agent-20
- Carboplatin + Paclitaxel-1
- Elacestrant-1
- Eribulin as a single agent or in combination-2
- Everolimus + Exemestane-4
- Fulvestrant as a single agent-0
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)-13
- Palbociclib + Fulvestrant-5
- Parp Inhibitors (Olaparib/Talazoparib)-0
- Pembrolizumab Monotherapy-0
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab-6
- Carboplatin + Paclitaxel + Pembrolizumab-6
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)-0
- Phesgo (Pertuzumab + Trastuzumab in a single injection)-36
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)-37
- Ribociclib + Fulvestrant-11
- Sacituzumab Govitecan-1
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent -16
- Trastuzumab deruxtecan (Enhertu)-3
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel-21
- Trastuzumab emtansine (Kadcyla)-4

- Any other active systemic anti-cancer therapy- none that can be identified from data source
- Aromatase Inhibitor as a single agent- this is prescribed in the community and MK pharmacy does not have access to this information

Q2. Does your trust participate in any clinical trials for breast cancer?

Yes

If so, please provide the name of each trial, and the number of patients taking part.

ATNEC: 34
POETIC-A: 40
SWEET: 15
ROSETA: 14
SMALL: 1
ENDONET: 0
PBCP - just opened

Follow-up:

ADD-ASPIRIN: 32
OPTIMA: 25
MARECA: 15

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.